CervoMed Inc.
CRVONasdaq
$3.08
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↓ -59.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.1M
Net Income (TTM)
-$30.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-1488.9%
Net Margin
-1438.0%
ROE
-283.0%
ROIC
—
Debt / Equity
—
Net Cash
$12.9M
Return 1Y
-59.3%
Company profile
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
- CEO
- John J. Alam
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- Massachusetts
- Website
- www.cervomed.com
Management & directors
- Elder William RobertCFO, GC & Secretary
- Winton MatthewChief Commercial and Business
- Alam John JCEO & President
Roles derived from SEC Form 4 filings.
Earnings
CRVO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $7.1M | $9.7M | $4.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.0M | -$24.7M | -$3.5M | -$7.8M | -$18.2M | -$28.3M |
| Net income | -$14.2M | -$24.1M | -$5.8M | -$2.2M | -$16.3M | -$27.0M |
| Diluted EPS | $53.8M | $1.9M | $2.0M | — | — | — |
| Operating cash flow | -$13.6M | -$14.5M | -$2.6M | -$7.4M | -$16.5M | -$23.4M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -109.3% | -187.2% | -706.2% |
| Net margin | — | — | — | -30.4% | -167.3% | -673.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.9M | $2.2M | $1.9M | $1.8M | $322,569.00 | $8,726.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.0M | -$5.4M | -$7.2M | -$5.3M | -$6.6M | -$8.0M | -$8.3M | -$8.1M |
| Net income | -$2.3M | -$4.8M | -$6.7M | -$4.9M | -$6.3M | -$7.7M | -$8.1M | -$8.0M |
| Diluted EPS | — | -$0.55 | — | — | — | — | — | — |
| Operating cash flow | -$2.2M | -$4.9M | -$8.1M | -$3.9M | -$6.5M | -$6.5M | -$6.6M | -$8.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -91.1% | -278.2% | -334.9% | -276.6% | -376.4% | -2493.8% | -95479.2% | — |
| Net margin | -70.4% | -245.1% | -310.1% | -255.2% | -356.1% | -2395.3% | -92722.0% | — |
Company news
Jun 18, 2026
- 32d agoCRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rallystocktwits.com
- 32d agoTop Midday Gainersfinance.yahoo.com
- 32d agoCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com
- 32d agoCervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)investorshub.advfn.com
- 32d agoCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | BOGER JOSHUA S | Buy | 955,414 | $3.14 | $3.0M | filing |
| 2025-11-18 | ELDER WILLIAM ROBERT· CFO, GC & Secretary | Buy | 2,500 | $8.32 | $20,800.00 | filing |
| 2025-11-18 | Winton Matthew· Chief Commercial and Business | Buy | 1,500 | $7.95 | $11,925.00 | filing |
| 2025-11-17 | Gregoire Sylvie | Buy | 10,807 | $8.46 | $91,427.22 | filing |
| 2025-11-17 | ALAM JOHN J· CEO & President | Buy | 10,807 | $8.46 | $91,427.22 | filing |
| 2025-11-17 | ALAM JOHN J· CEO & President | Buy | 10,793 | $8.46 | $91,308.78 | filing |
| 2025-11-17 | Gregoire Sylvie | Buy | 10,793 | $8.46 | $91,308.78 | filing |
| 2025-11-17 | Winton Matthew· Chief Commercial and Business | Buy | 3,500 | $8.43 | $29,505.00 | filing |
| 2025-11-17 | ELDER WILLIAM ROBERT· CFO, GC & Secretary | Buy | 1,000 | $8.45 | $8,450.00 | filing |
| 2025-11-14 | Winton Matthew· Chief Commercial and Business | Buy | 10,000 | $7.57 | $75,700.00 | filing |
| 2025-11-14 | Gregoire Sylvie | Buy | 1,707 | $7.57 | $12,921.99 | filing |
| 2025-11-14 | ALAM JOHN J· CEO & President | Buy | 1,707 | $7.57 | $12,921.99 | filing |
| 2025-11-14 | Gregoire Sylvie | Buy | 1,693 | $7.55 | $12,782.15 | filing |
| 2025-11-14 | ALAM JOHN J· CEO & President | Buy | 1,693 | $7.55 | $12,782.15 | filing |
| 2025-11-13 | ALAM JOHN J· CEO & President | Buy | 4,447 | $7.51 | $33,396.97 | filing |
| 2025-11-13 | Gregoire Sylvie | Buy | 4,447 | $7.51 | $33,396.97 | filing |
| 2025-11-12 | Gregoire Sylvie | Buy | 5,553 | $7.35 | $40,814.55 | filing |
| 2025-11-12 | ALAM JOHN J· CEO & President | Buy | 5,553 | $7.35 | $40,814.55 | filing |
| 2025-11-12 | ELDER WILLIAM ROBERT· CFO, GC & Secretary | Buy | 3,500 | $7.44 | $26,040.00 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.